Skip to content
VuFind
Advanced
  • Phase 1b dose-finding study of...
  • Cite this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
QR Code

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

Bibliographic Details
Main Authors: De Boer, R., Kotasek, D., White, S., Koczwara, B., Mainwaring, P., Chan, Arlene, Melara, R., Ye, Y., Adewoye, A., Sikorski, R., Kaufman, P.
Format: Journal Article
Published: Springer New York LLC 2012
Online Access:http://hdl.handle.net/20.500.11937/18532
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://hdl.handle.net/20.500.11937/18532

Similar Items

  • Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    by: Miles, D., et al.
    Published: (2010)
  • Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    by: Miles, D., et al.
    Published: (2013)
  • Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
    by: Jabir, Rafid, et al.
    Published: (2014)
  • Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
    by: Dent, R., et al.
    Published: (2013)
  • Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    by: Chan, Arlene, et al.
    Published: (2014)

Search Options

  • Advanced Search

Find More

  • Browse the Catalog

Need Help?

  • Search Tips